Schleimer Robert P
Department of Medicine, Division of Allergy-Immunology, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611; email:
Annu Rev Pathol. 2017 Jan 24;12:331-357. doi: 10.1146/annurev-pathol-052016-100401. Epub 2016 Dec 5.
Chronic rhinosinusitis (CRS) is a troublesome, chronic inflammatory disease that affects over 10% of the adult population, causing decreased quality of life, lost productivity, and lost time at work and leading to more than a million surgical interventions annually worldwide. The nose, paranasal sinuses, and associated lymphoid tissues play important roles in homeostasis and immunity, and CRS significantly impairs these normal functions. Pathogenic mechanisms of CRS have recently become the focus of intense investigations worldwide, and significant progress has been made. The two main forms of CRS that have been long recognized, with and without nasal polyps, are each now known to be heterogeneous, based on underlying mechanism, geographical location, and race. Loss of the immune barrier, including increased permeability of mucosal epithelium and reduced production of important antimicrobial substances and responses, is a common feature of many forms of CRS. One form of CRS with polyps found worldwide is driven by the cytokines IL-5 and IL-13 coming from Th2 cells, type 2 innate lymphoid cells, and probably mast cells. Type 2 cytokines activate inflammatory cells that are implicated in the pathogenic mechanism, including mast cells, basophils, and eosinophils. New classes of biological drugs that block the production or action of these cytokines are making important inroads toward new treatment paradigms in polypoid CRS.
慢性鼻-鼻窦炎(CRS)是一种棘手的慢性炎症性疾病,影响着超过10%的成年人口,导致生活质量下降、工作效率降低以及工作时间损失,并且在全球范围内每年导致超过一百万次手术干预。鼻子、鼻窦及相关淋巴组织在体内平衡和免疫中发挥着重要作用,而CRS会显著损害这些正常功能。CRS的发病机制最近已成为全球深入研究的焦点,并取得了重大进展。长期以来被认可的CRS的两种主要形式,即伴鼻息肉和不伴鼻息肉的CRS,现在基于潜在机制、地理位置和种族,每种形式都被认为是异质性的。免疫屏障的丧失,包括黏膜上皮通透性增加以及重要抗菌物质和反应的产生减少,是多种形式CRS的共同特征。在全球范围内发现的一种伴有息肉的CRS形式是由来自Th2细胞、2型固有淋巴细胞以及可能还有肥大细胞的细胞因子IL-5和IL-13驱动的。2型细胞因子激活参与发病机制的炎症细胞,包括肥大细胞、嗜碱性粒细胞和嗜酸性粒细胞。阻断这些细胞因子产生或作用的新型生物药物正在为息肉样CRS的新治疗模式带来重要突破。